Food, Drugs, Healthcare, Life Sciences

On 8 September 2025, the Court of Justice of the European Union (CJEU) received a preliminary request from the Bundesverwaltungsgericht...

Volatile equity markets and costly debt are fueling interest in monetization transactions. Data, recent deals, and increasing interest suggest the model is set to endure.

In late September, the U.S. Food & Drug Administration ("FDA") issued three draft guidances related to cell and gene therapy ("CGT") products...

The PPE Medpro case has been widely reported. But the coverage has not focused, as we do, on the contractual interpretation, estoppel, and mitigation angles.

Businesses across many industries naturally want to showcase their satisfied customers. Whether it's a university featuring successful graduates, a retailer highlighting happy shoppers...

On 8 September 2025, the Court of Justice of the European Union (CJEU) received a preliminary request from the Bundesverwaltungsgericht...

The aflibercept multi-district litigation consists of multiple actions consolidated in the Northern District of West Virginia, with Regeneron Pharmaceuticals, Inc. ("Regeneron") filing suit under the Biologics...

Volatile equity markets and costly debt are fueling interest in monetization transactions. Data, recent deals, and increasing interest suggest the model is set to endure.

Steptoe partners Joseph Dages, Ryan Poscablo, and Anthony Anscombe and associate Emma Howard authored an article titled "Key Considerations for Food Safety Recalls," which appeared in Food Safety Magazine.

In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit upheld the district court’s determination that the claims at issue were neither obvious nor invalid under the doctrine of obviousness-type double patenting based on a "lead compound" approach to the obviousness determinations.

After the Supreme Court decided that the personalized medicine method claims at issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc. did not satisfy the patent eligibility requirements of 35 USC § 101.

GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.